$0.91 3.9%
ASRT Stock Price vs. AI Score
Data gathered: December 26

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Assertio Therapeutics (ASRT)

Analysis generated February 17, 2024. Powered by Chat GPT.

Assertio Therapeutics is a pharmaceutical company known for its work in the development, commercialization, and sale of branded prescription medicines aimed at addressing significant needs in pain management and other neurological illnesses. The company's portfolio currently includes products that help manage conditions such as migraines, postherpetic neuralgia, and cancer-related pain.

Read full AI stock Analysis

Stock Alerts - Assertio Therapeutics (ASRT)

company logo Assertio Therapeutics | December 20
Price is up by 5.4% in the last 24h.
company logo Assertio Therapeutics | December 19
Price is down by -5.1% in the last 24h.
company logo Assertio Therapeutics | December 18
Price is down by -5.5% in the last 24h.
company logo Assertio Therapeutics | December 13
Price is down by -5.2% in the last 24h.

About Assertio Therapeutics

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system.


Assertio Therapeutics
Price $0.91
Target Price Sign up
Volume 110,750
Market Cap $82M
Year Range $0.77 - $1.75
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2429M31M-1.7M-2.9M3.6M-0.030
Q2 '2431M34M-2.8M-3.7M3.1M-0.040
Q1 '2432M36M-4.3M-4.5M2M-0.050
Q4 '2332M82M-49M-57M-26M-0.610
Q3 '2335M280M-245M-280M-218M-0.460

Insider Transactions View All

Mason Heather L filed to buy 287,650 shares at $0.8.
November 19 '24
O'Grady Brendan P. filed to buy 11,706 shares at $0.9.
November 15 '24
Vacirca Jeff L filed to buy 151,159 shares at $1.1.
June 12 '24
Mason Heather L filed to buy 212,650 shares at $1.
June 6 '24
Tyree James L filed to sell 188,251 shares at $1.1.
March 15 '24

What is the Market Cap of Assertio Therapeutics?

The Market Cap of Assertio Therapeutics is $82M.

What is the current stock price of Assertio Therapeutics?

Currently, the price of one share of Assertio Therapeutics stock is $0.91.

How can I analyze the ASRT stock price chart for investment decisions?

The ASRT stock price chart above provides a comprehensive visual representation of Assertio Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Assertio Therapeutics shares. Our platform offers an up-to-date ASRT stock price chart, along with technical data analysis and alternative data insights.

Does ASRT offer dividends to its shareholders?

As of our latest update, Assertio Therapeutics (ASRT) does not offer dividends to its shareholders. Investors interested in Assertio Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Assertio Therapeutics?

Some of the similar stocks of Assertio Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.